Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of everolimus on tacrolimus pharmacokinetics in stable renal transplant patients
2005-001102-31Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tacrolimus and everolimus in Kidney allograft status (RTx) and kidney allograft rejection (3 arms), sponsored by Astellas Pharma. Primary endpoints: Tacrolimus AUC0-24h single dose, Tacrolimus AUC0-24h steady state and 2 more. Started Dec 2005; status: completed.
02
Drugs
tacrolimuseverolimus
03
Conditions
Kidney allograft status (RTx)kidney allograft rejection
Beyond the preview
Go deeper on 2005-001102-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001102-31.